1.Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis.
Xiao-Jian ZHOU ; Zhen QIN ; Jiao LU ; Jian-Guo HONG
Chinese Medical Journal 2021;134(24):2954-2961
BACKGROUND:
Despite the recommendation of inhaled corticosteroids (ICSs) plus long-acting beta 2-agonist (LABA) and leukotriene receptor antagonist (LTRA) or ICS/LTRA as stepwise approaches in asthmatic children, there is a lack of published systematic review comparing the efficacy and safety of the two therapies in children and adolescents aged 4 to 18 years. This study aimed to compare the safety and efficacy of salmeterol/fluticasone (SFC) vs. montelukast (MON), or combination of montelukast and fluticasone (MFC) in children and adolescents aged 4 to 18 years with bronchial asthma.
METHODS:
A systematic search was conducted in MEDLINE, EMBASE, the Cochrane Library, China BioMedical Literature Database, Chinese National Knowledge Infrastructure, VIP Database for Chinese Technical Periodical, and Wanfang for randomized controlled trials (RCTs) published from inception to May 24, 2021. Interventions are as follows: SFC vs. MON, or combination of MFC, with no limitation of dosage or duration. Primary and secondary outcome measures were as follows: the primary outcome of interest was the risk of asthma exacerbation. Secondary outcomes included risk of hospitalization, pulmonary function, asthma control level, quality of life, and adverse events (AEs). A random-effects (I2 ≥ 50%) or fixed-effects model (I2 < 50%) was used to calculate pooled effect estimates, comparing the outcomes between the intervention and control groups where feasible.
RESULTS:
Of the 1006 articles identified, 21 studies met the inclusion criteria with 2643 individuals; two were at low risk of bias. As no primary outcomes were similar after an identical treatment duration in the included studies, meta-analysis could not be performed. However, more studies favored SFC, instead of MON, owing to a lower risk of asthma exacerbation in the SFC group. As for secondary outcome, SFC showed a significant improvement of peak expiratory flow (PEF)%pred after 4 weeks compared with MFC (mean difference [MD]: 5.45; 95% confidence interval [CI]: 1.57-9.34; I2 = 95%; P = 0.006). As for asthma control level, SFC also showed a higher full-controlled level (risk ratio [RR]: 1.51; 95% CI: 1.24-1.85; I2 = 0; P < 0.001) and higher childhood asthma control test score after 4 weeks of treatment (MD: 2.30; 95% CI: 1.39-3.21; I2 = 72%; P < 0.001) compared with MFC.
CONCLUSIONS:
SFC may be more effective than MFC for the treatment of asthma in children and adolescents, especially in improving asthma control level. However, there is insufficient evidence to make firm conclusive statements on the use of SFC or MON in children and adolescents aged 4 to 18 years with asthma. Further research is needed, particularly a combination of good-quality long-term prospective studies and well-designed RCTs.
PROSPERO REGISTRATION NUMBER
CRD42019133156.
Acetates
;
Administration, Inhalation
;
Adolescent
;
Adrenal Cortex Hormones/therapeutic use*
;
Albuterol/therapeutic use*
;
Anti-Asthmatic Agents/therapeutic use*
;
Asthma/drug therapy*
;
Child
;
Cyclopropanes
;
Drug Therapy, Combination
;
Fluticasone/therapeutic use*
;
Humans
;
Quinolines
;
Salmeterol Xinafoate/therapeutic use*
;
Sulfides
2.Efficacy and Safety of Roflumilast in Korean Patients with COPD.
Jae Seung LEE ; Yoon Ki HONG ; Tae Sun PARK ; Sei Won LEE ; Yeon Mok OH ; Sang Do LEE
Yonsei Medical Journal 2016;57(4):928-935
PURPOSE: Roflumilast is the only oral phosphodiesterase 4 inhibitor approved to treat chronic obstructive pulmonary disease (COPD) patients [post-bronchodilator forced expiratory volume in 1 second (FEV1) <50% predicted] with chronic bronchitis and a history of frequent exacerbations. This study evaluated the efficacy and safety of roflumilast in Korean patients with COPD and compared the efficacy based on the severity of airflow limitation. MATERIALS AND METHODS: A post-hoc subgroup analysis was performed in Korean COPD patients participating in JADE, a 12-week, double-blinded, placebo-controlled, parallel-group, phase III trial in Asia. The primary efficacy endpoint was the mean [least-squares mean adjusted for covariates (LSMean)] change in post-bronchodilator FEV1 from baseline to each post-randomization visit. Safety endpoints included adverse events (AEs) and changes in laboratory values, vital signs, and electrocardiograms. RESULTS: A total of 260 Korean COPD patients were recruited, of which 207 were randomized to roflumilast (n=102) or placebo (n=105) treatment. After 12 weeks, LSMean post-bronchodilator FEV1 increased by 43 mL for patients receiving roflumilast and decreased by 60 mL for those taking placebo. Adverse events were more common in the roflumilast group than in the placebo group; however, the types and frequency of AEs were comparable to those reported in previous studies. CONCLUSION: Roflumilast significantly improved lung function with a tolerable safety profile in Korean COPD patients irrespective of the severity of airflow limitation.
Aged
;
Aminopyridines/*therapeutic use
;
*Asian Continental Ancestry Group
;
Benzamides/*therapeutic use
;
Cyclopropanes/therapeutic use
;
Double-Blind Method
;
Female
;
Humans
;
Male
;
Middle Aged
;
Phosphodiesterase 4 Inhibitors/*therapeutic use
;
Pulmonary Disease, Chronic Obstructive/*drug therapy/*ethnology/physiopathology
;
Republic of Korea
;
Respiratory Function Tests
;
Treatment Outcome
3.Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Huan XIA ; Xiao-Jie HUANG ; Yue HU ; Li-Ying GAO ; Yue WU ; Hao WU ; Zhong-Fang YAN ; Ping MA
Chinese Medical Journal 2021;134(23):2850-2856
BACKGROUND:
Central nervous system (CNS) symptoms after efavirenz (EFV) treatment in people living with human immunodeficiency virus (HIV) could persist and impact their quality of life. We assessed the impact of EFV-based regimen replacement with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), which is considered an alternative option for subjects who do not tolerate EFV. Most specifically, we assessed the safety and the efficacy of E/C/F/TAF and its effects on the participants' neuropsychiatric toxicity symptoms in a real-life setting.
METHODS:
A prospective cohort study was conducted among virologic suppressed HIV-positive participants receiving EFV-based regimens with ongoing CNS toxicity ≥ grade 2. The participants were switched to single-pill combination regimens E/C/F/TAF and followed up for 48 weeks. The neuropsychiatric toxicity symptoms were measured using a CNS side effects questionnaire, as well as the Hospital Anxiety and Depression Scale and the Pittsburgh Sleep Quality Index. The primary outcome measure was the proportion of participants experiencing grade 2 or higher CNS toxicity after EFV switch off at weeks 12, 24, and 48. Secondary endpoints included virologic and immunological responses and the effect on fasting lipids at week 48 after switch.
RESULTS:
One hundred ninety-six participants (96.9% men, median age: 37.5 years, median: 3.7 years on prior EFV-containing regimens) were included in the study. Significant improvements in anxiety and sleep disturbance symptoms were observed at 12, 24, and 48 weeks after switching to E/C/F/TAF (P < 0.05). No significant change in depression symptom scores was observed. At 48 weeks after switch, HIV viral load <50 copies/mL was maintained in all of the participants, median fasting lipid levels were moderately increased (total cholesterol [TC]: 8.2 mg/dL, low-density lipoprotein cholesterol [LDL-C]: 8.5 mg/dL, high-density lipoprotein cholesterol [HDL-C]: 2.9 mg/dL, and triglyceride (TG): 1.6 mg/dL, and the TC:HDL-C ratio remained stable.
CONCLUSIONS
The single-pill combination regimens E/C/F/TAF is safe and well tolerated. This study reveals that switching from EFV to E/C/F/TAF significantly reduces neuropsychiatric toxicity symptoms in people living with HIV with grade 2 or higher CNS complaints.
Adenine/therapeutic use*
;
Adult
;
Alanine
;
Alkynes
;
Anti-HIV Agents/adverse effects*
;
Benzoxazines
;
Central Nervous System
;
Cobicistat/therapeutic use*
;
Cyclopropanes
;
Drug Combinations
;
Emtricitabine/therapeutic use*
;
Female
;
HIV Infections/drug therapy*
;
Humans
;
Male
;
Prospective Studies
;
Quality of Life
;
Quinolones
;
Sleep Quality
;
Tenofovir/analogs & derivatives*
4.Chemokine Receptor CXCR3 in the Spinal Cord Contributes to Chronic Itch in Mice.
Peng-Bo JING ; De-Li CAO ; Si-Si LI ; Meixuan ZHU ; Xue-Qiang BAI ; Xiao-Bo WU ; Yong-Jing GAO
Neuroscience Bulletin 2018;34(1):54-63
Recent studies have shown that the chemokine receptor CXCR3 and its ligand CXCL10 in the dorsal root ganglion mediate itch in experimental allergic contact dermatitis (ACD). CXCR3 in the spinal cord also contributes to the maintenance of neuropathic pain. However, whether spinal CXCR3 is involved in acute or chronic itch remains unclear. Here, we report that Cxcr3 mice showed normal scratching in acute itch models but reduced scratching in chronic itch models of dry skin and ACD. In contrast, both formalin-induced acute pain and complete Freund's adjuvant-induced chronic inflammatory pain were reduced in Cxcr3 mice. In addition, the expression of CXCR3 and CXCL10 was increased in the spinal cord in the dry skin model induced by acetone and diethyl ether followed by water (AEW). Intrathecal injection of a CXCR3 antagonist alleviated AEW-induced itch. Furthermore, touch-elicited itch (alloknesis) after compound 48/80 or AEW treatment was suppressed in Cxcr3 mice. Finally, AEW-induced astrocyte activation was inhibited in Cxcr3 mice. Taken together, these data suggest that spinal CXCR3 mediates chronic itch and alloknesis, and targeting CXCR3 may provide effective treatment for chronic pruritus.
Acetamides
;
therapeutic use
;
Animals
;
Chemokine CXCL10
;
metabolism
;
Chloroquine
;
toxicity
;
Chronic Disease
;
Cyclopropanes
;
adverse effects
;
Dehydration
;
complications
;
Dinitrofluorobenzene
;
adverse effects
;
Disease Models, Animal
;
Formaldehyde
;
toxicity
;
Freund's Adjuvant
;
toxicity
;
Mice
;
Mice, Inbred C57BL
;
Mice, Knockout
;
Motor Activity
;
drug effects
;
Pain
;
chemically induced
;
Pruritus
;
chemically induced
;
pathology
;
Pyrimidines
;
therapeutic use
;
Receptors, CXCR3
;
antagonists & inhibitors
;
genetics
;
metabolism
;
Skin
;
pathology
;
Spinal Cord
;
drug effects
;
metabolism
;
pathology
;
Time Factors
;
p-Methoxy-N-methylphenethylamine
;
toxicity